Latent Labs has launched LatentX, a web-based AI model for protein design, six months after securing $50 million in funding. The model aims to democratise access to advanced protein engineering for researchers and pharmaceutical companies.
LatentX has demonstrated state-of-the-art performance in lab tests, with high viability rates in designed proteins. Unlike AlphaFold's structure prediction, LatentX generates novel biological entities, potentially accelerating drug discovery and reducing costs for previously untreatable conditions. The company's licensing model prioritises accessibility, offering free access while planning paid advanced features to sustain innovation.
Latent Labs' commitment to accessibility is a key aspect of its approach, offering a web-based model that can be accessed by a wide range of users. This empowers both academic researchers and large pharmaceutical companies to design novel proteins directly from their web browsers.
Related Articles

AI Repurposes Diabetes Drug
Read more about AI Repurposes Diabetes Drug →
Biological Computer Lab-Grown Neurons
Read more about Biological Computer Lab-Grown Neurons →
Insilico's AI cancer drug trial
Read more about Insilico's AI cancer drug trial →
AI 'Hallucinations' Remain Problematic
Read more about AI 'Hallucinations' Remain Problematic →
